Beta Bionics, Inc. (BBNX) · Oct 27, 2026 · Earnings
Beat — Revenue $35.5M vs approximately $33.6M consensus
Beta Bionics’ Q3 earnings beat revenue expectations and lifted 2026 guidance, but wider losses and a 3D algorithm reset keep the launch story unfinished.
Beta Bionics is a commercial-stage diabetes-device company trying to expand beyond its iLet insulin system with the Mint patch pump and next-generation algorithms, while still addressing FDA quality-system scrutiny. Its current commercial base remains heavily dependent on iLet, making the shift toward Mint and broader pharmacy reimbursement central to the story.
| Metric | Q3 2026 | Q3 2025 / prior guide | Read |
|---|---|---|---|
| Revenue | $35.5M | $27.3M | Above published consensus of roughly $33.6M |
| Gross margin | 57.3% | 55.5% | Improved year over year |
| Net loss | $(24.4)M | $(14.2)M | Loss widened |
| Adjusted EBITDA | $(18.9)M | $(12.2)M | Loss widened |
| 2026 revenue guidance | $124M–$126M | $121M–$126M | Low end raised; high end unchanged |
| Cash, cash equivalents and investments | $373.6M | $264.6M at Dec. 31, 2025 | Funding strengthened |
The quarter beat on revenue, but the quality of growth is mixed. Revenue rose 30% year over year to $35.5 million, ahead of the roughly $33.6 million published consensus, while gross margin improved to 57.3% from 55.5%. However, DME-channel sales grew only 4%, and iLet sales through that channel fell to $11.6 million from $14.2 million. The growth engine was largely single-use products sold through the PBP channel, which drove total PBP revenue to $13.6 million from $6.2 million.
The business is growing faster, but spending is outrunning that growth. Operating expenses climbed to $46.9 million from $32.2 million, led by higher sales and marketing and research-and-development costs. As a result, the operating loss widened to $26.6 million from $17.0 million, while adjusted EBITDA deteriorated to negative $18.9 million from negative $12.2 million.
Guidance improved modestly, but the company is already warning about a near-term Mint transition effect. The 2026 revenue range moved from $121 million–$126 million to $124 million–$126 million, which is a low-end lift rather than a full-range upgrade. Management also disclosed that prospective iLet users could defer purchases while waiting for Mint, potentially shifting as much as $8.5 million of revenue out of the fourth quarter.
The capital raise gives Beta Bionics room to fund the product transition, but the regulatory path for its next algorithm just became less clean. The company ended the quarter with $373.6 million in cash, cash equivalents and investments after raising approximately $161.3 million net, supporting Mint manufacturing, clinical work and commercialization. But it withdrew the 3D Intelligence 510(k) application after FDA interactions and now plans to submit additional simulator-validation data in mid-Q4. Mint itself remains FDA-cleared, while the 3D algorithm launch depends on another regulatory step.
Bottom line: This was a narrow earnings beat with a small guidance lift and much better funding, but the underlying mix still shows iLet pressure, widening losses and a regulatory reset for 3D Intelligence. The event advances the commercial story, without removing the execution risk around the Mint transition and next algorithm launch.
Revised 3D Intelligence 510(k) submission, mid-Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!